2,400 Shares in Amgen Inc. $AMGN Acquired by Redwood Investment Management LLC

Redwood Investment Management LLC purchased a new stake in Amgen Inc. (NASDAQ:AMGN) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,400 shares of the medical research company’s stock, valued at approximately $869,000.

Several other hedge funds have also added to or reduced their stakes in the business. Norges Bank acquired a new position in shares of Amgen in the fourth quarter valued at $2,164,162,000. Bank of America Corp DE acquired a new stake in shares of Amgen during the 2nd quarter worth about $1,831,903,000. Capital World Investors lifted its stake in shares of Amgen by 22.9% during the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after buying an additional 4,302,237 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of Amgen by 4.8% during the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock worth $17,874,974,000 after buying an additional 2,261,544 shares during the period. Finally, State Street Corp boosted its holdings in shares of Amgen by 4.4% during the 4th quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock worth $10,012,872,000 after buying an additional 1,287,310 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Tezspire posted strong Phase 3 results in eosinophilic esophagitis (EoE). The drug met both co-primary and all key secondary endpoints, producing statistically significant and clinically meaningful improvements in tissue inflammation and difficulty swallowing. Benefits were sustained through 52 weeks, supporting a potential third approved indication beyond asthma and chronic rhinosinusitis with nasal polyps. Tezspire Phase 3 results
• Positive Sentiment: The EoE opportunity could materially expand Tezspire’s commercial potential. Analysts and industry commentators view EoE as a possible blockbuster market, potentially allowing Amgen and partner AstraZeneca to compete more directly with established biologics such as Dupixent. Regulatory filing and approval remain necessary before the opportunity can translate into revenue. Tezspire EoE market opportunity
• Neutral Sentiment: Amgen began a Phase 1 study of AMG 691 aimed at a potentially important Asian market. The trial could add a long-term growth asset, but it is at an early stage and provides limited near-term earnings visibility. AMG 691 Phase 1 trial
• Negative Sentiment: Amgen ended its Crohn’s disease research collaboration with TScan Therapeutics. The decision removes an exclusive effort to identify and develop T-cell targets in inflammatory bowel disease, narrowing one element of Amgen’s early pipeline and highlighting uncertainty around its partnership strategy. Amgen ends Crohn’s disease partnership

Analyst Ratings Changes

AMGN has been the topic of several research analyst reports. Barclays increased their price target on shares of Amgen from $360.00 to $380.00 and gave the company an “equal weight” rating in a report on Friday, August 14th. Cantor Fitzgerald upped their target price on Amgen from $350.00 to $400.00 and gave the company a “neutral” rating in a research report on Tuesday, August 18th. Piper Sandler increased their target price on Amgen from $427.00 to $457.00 and gave the stock an “overweight” rating in a research note on Thursday, August 20th. UBS Group lifted their price target on Amgen from $420.00 to $440.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Finally, Morgan Stanley restated an “overweight” rating and issued a $362.00 price target on shares of Amgen in a research note on Wednesday, August 19th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, Amgen currently has a consensus rating of “Hold” and an average price target of $380.43.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the sale, the senior vice president directly owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Rachna Khosla sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at approximately $2,642,098.28. This represents a 23.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 6,222 shares of company stock valued at $2,540,926 in the last three months. Company insiders own 0.85% of the company’s stock.

Amgen Trading Down 0.8%

Shares of AMGN stock opened at $436.99 on Friday. Amgen Inc. has a fifty-two week low of $269.77 and a fifty-two week high of $447.03. The stock’s fifty day moving average price is $386.75 and its two-hundred day moving average price is $364.23. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. The company has a market cap of $236.25 billion, a PE ratio of 27.16, a P/E/G ratio of 3.18 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The company had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. During the same quarter in the previous year, the firm earned $6.02 EPS. Amgen’s revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities analysts predict that Amgen Inc. will post 22.92 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be paid a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.3%. Amgen’s payout ratio is presently 62.65%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.